跳至主要内容
临床试验/JPRN-jRCT2080223588
JPRN-jRCT2080223588已完成3 期

A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients With Partial Onset Seizures (Including Secondarily Generalized Seizures)

Eisai Co., Ltd.0 个研究点目标入组 89 人开始时间: 2017年7月14日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
89

研究概览

简要总结

Monotherapy treatment with perampanel at doses of 4 mg and 8 mg was effective in achieving seizure-free status for at least 26 weeks in untreated subjects with POS. Monotherapy treatment with perampanel at doses of 4 mg and 8 mg was safe and well tolerated. No new safety signals were identified for monotherapy treatment with perampanel.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 12age old 至 <= 74age old(—)
性别
All

入选标准

  • (1)Be considered reliable and willing to be available for the study period and are able to record seizures and report adverse events (AEs) himself/herself or have a caregiver who can record seizures and report AEs for them
  • (2)Participants who are newly diagnosed or recurrent epilepsy
  • (3)Participants who have excluded the progressive central nervous system (CNS) abnormality occurring seizures by computed tomography (CT) or magnetic resonance imaging (MRI)
  • (4)Participants who have had a diagnosis of epilepsy with partial seizures with or without secondarily generalized seizures

排除标准

  • (1)Participants who present only simple partial seizures without motor signs
  • (2)Participants who have seizure clusters where individual seizures cannot be counted
  • (3)Participants who present or have a history of Lennox-Gastaut syndrome
  • (4)Participants who have a history of status epilepticus
  • (5)Participants who have a history of psychogenic non-epileptic seizures

研究者

相似试验